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 Abstract 
 Background/Aims: Oligomerization of amyloid beta (A  ) is a hypothesized step in the formation 
of plaques in Alzheimer’s disease (AD) but has been difficult to demonstrate in vivo in humans. As 
persons destined to develop familial AD (FAD) due to fully penetrant autosomal dominant muta-
tions are essentially certain to develop the disease, they provide the opportunity to identify oligo-
mers during the presymptomatic stage of the disease.  Methods: We measured levels of A  42 using 
a conventional immunoassay and prefibrillar, fibrillar, and annular protofibrillar oligomers using 
polyclonal conformation-dependent antibodies in the cerebrospinal fluid (CSF) of 7 persons at risk 
for inheriting FAD mutations. Levels of oligomers were compared between FAD mutation carriers 
and noncarriers.  Results: Compared to 2 noncarriers, annular protofibrillar oligomers were elevat-
ed, prefibrillar and fibrillar oligomers trended towards elevation and A  42 monomer trended to-
wards being decreased in 5 FAD mutation carriers.  Conclusion: Our data provide evidence for an 
identifiable elevation of CSF oligomers during the presymptomatic phase of FAD. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The ‘amyloid hypothesis’ of the pathogenesis of Alzheimer’s disease (AD) posits that an 
increased production or a decreased degradation of derivatives of the amyloid precursor pro-
tein (APP) initiate a cascade of events that cause the illness  [1] . This hypothesis is based in 
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part on the observation that causative autosomal dominant familial AD (FAD) mutations 
cause absolute or relative increases in the amount of the 42-amino acid length version of the 
peptide produced by cleavage of APP (A  42 )  [2] . Also, the amyloid plaques in the brain that 
define the illness are largely composed of derivatives of APP, and the deposition of A  42 is 
an early event in their formation  [3] . However, there is an imperfect association between the 
degree of amyloid deposition and patient clinical status, and intervention studies have sug-
gested that it may be possible to decrease plaque pathology without significant impact on the 
disease course  [4] . There has been an increasing focus on soluble forms of A  as being more 
crucial to the development of AD than the plaques per se, with various forms of A  oligomers 
being identified and characterized. Such oligomers have been demonstrated to exert toxic 
effects on synapses independently of plaque formation  [5] . 
 Despite the pivotal role posited for A  in the cause of AD, measurements of monomeric 
A  42 in the cerebrospinal fluid (CSF) of persons with AD  [6] or destined to develop it  [7] have 
found it to be decreased relative to controls. It has been hypothesized that this decrement 
represents a shift in equilibrium from the monomeric form to oligomeric or insoluble forms 
in the brain, but evidence for this is indirect. A recent study found decreased A  42 concur-
rent with elevated A  oligomers in the CSF in a population with late-onset AD using an 
enzyme-linked immunosorbent assay (ELISA)  [8] . 
 As the pathogenic process of AD begins years before overt symptoms in persons carry-
ing FAD mutations  [7, 9] , we hypothesized that A  oligomers would be elevated in the CSF 
of asymptomatic FAD mutation carriers at a time when A  42 measured using conventional 
techniques would be decreased. In the current study, we measured oligomers using confor-
mation-dependent antibodies and A  42 using standard ELISA techniques in 7 asymptom-
atic persons at risk for developing FAD due to  PSEN1 and  APP mutations. 
 Materials and Methods 
 The study population consisted of the initial 7 subjects who underwent lumbar punc-
tures in an ongoing study of clinical, imaging, and biochemical changes occurring during 
the presymptomatic phase of FAD. Among the 7 subjects, 2 were cousins at risk for the L235V 
 PSEN1 mutation  [10] , 4 were siblings at risk for the A431E  PSEN1 mutation  [11] , and 1 was at 
risk for the V717I  APP mutation  [12] . The subjects underwent comprehensive cognitive as-
sessments including the Clinical Dementia Rating (CDR)  [13] scale blind to their genetic 
status as previously described  [14] . All study procedures were performed in accordance with 
the Helsinki Declaration of 1975 and were approved by the UCLA Institutional Review 
Board; all subjects provided written informed consent.  
 Blood was drawn and DNA extracted using standard techniques. The presence of the 
A431E and L235V substitutions in  PSEN1 was assessed using RFLP analyses, and the pres-
ence of the V717I substitution in  APP was assessed with direct sequencing. CSF was obtained 
and A  42 levels determined using Luminex Reagents and X-MAP technology as previously 
described  [15] .
 CSF samples were analyzed using dot-blot assays employing polyclonal A11 (anti-prefi-
brillar oligomer), OC (anti-fibrillar oligomer) and   APF (anti-annular protofibril) antibod-
ies as previously described  [16–18] . The total protein concentration was determined using 
the BCA Protein Assay kit (Pierce 23223 and 23224). The samples were diluted with PBS pH 
7.4 so that all samples had equal amounts of total protein. Diluted CSF samples were spotted 
onto nitrocellulose membrane BA-83 (Whatman 10 402 495) at 0.9–1.6   g in 2   l and al-
lowed to air dry. Blots were then incubated in 10% milk in Low-Tween-TBS (20 m M Tris, 137 
m M NaCl, 0.01% Tween 20, pH 7.6) for 1 h at room temperature. After three 5-min washes 
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in Low-Tween-TBS, the blots were incubated overnight at 4 o C in primary antibody solution 
(A11 1: 2,000,   APF 1: 1,000, and OC 1: 10,000) with 5% milk in Low-Tween-TBS, 0.02% NaN 3 . 
After three 5-min washes, the blots were incubated in goat-  -rabbit HRP-conjugated anti-
body (Jackson ImmunoResearch 305-035-0045, 1: 12,000), 5% milk in Low-Tween-TBS for
1 h at room temperature. Following the final three 5 min washes, the blots were incubated 
in ECL reagent (Amersham, RPN2106) for 1 min and exposed to film (Denville, E-3012). 
Oligomer concentration was quantified using densitometry as previously described  [19] .
 The age and A  42 , A11, OC, and   APF levels were compared between mutation carriers 
and noncarriers using Student’s t tests. 
 Results 
 Five subjects were mutation carriers (specific mutations not revealed secondary to sub-
ject confidentiality) and 2 were noncarriers. All subjects were asymptomatic (CDR scores = 
0). The subjects did not differ in absolute age or age relative to the typical age of dementia 
diagnosis in their families ( table 1 ). Levels of annular protofibrils were significantly elevated 
in mutation carriers relative to noncarriers (70.2 vs. 4.8, p = 0.02). Though levels of the other 
oligomers were not significantly different, all tended to be higher in mutation carries, where-
as A  42 levels tended to be lower ( table 1 ;  fig. 1 ). 
 Discussion  
 We present initial evidence for elevated oligomers measured using conformation-depen-
dent antibodies in the CSF of asymptomatic persons inheriting FAD mutations. Levels of 
A  42 measured using conventional immunoassays showed a trend in the opposite direction 
as has been well described, including in the current population  [15, 20] . Though the higher 
level of oligomers was not statistically significant except in the case of annular protofibrils, 
the consistent trend across antibodies in the context of a trend for decreased A  42 suggests 
the possibility of oligomerization of A  into a form not detectable by standard immunoas-
says for A  42 . These results are consistent with those of a recent report of elevated levels of 
annular protofibrils in the brain of AD subjects  [21] .
 Though our conclusions are limited by the small number of subjects, our findings are 
consistent with the presence of an identifiable intermediate state between A  42 monomers 
and the deposition of A  42 in insoluble plaques during the presymptomatic phase of FAD. 
Table 1. A ge and CSF A42 and oligomer levels in FAD mutation carriers and noncarriers (mean 8 SD)
Carriers
(n = 5)
Noncarriers
(n = 2)
p
Age, years 3386.8 30.582.1 0.65
Years younger than family-specific age of
dementia diagnosis 14.486.3 13.082.8 0.79
CSF A42, pg/ml 260.08144.0 415.6880.7 0.22
CSF A11 reactivity 38.4818.6 22.584.6 0.31
CSF OC reactivity 13.887.1 3.381.9 0.11
CSF APF reactivity 70.2810.0 44.886.1 0.02
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Our findings are consistent with the previous observation that at least a part of the decre-
ment of CSF A  42 levels seen in AD patients is eliminated when A  42 levels are measured in 
denaturing conditions that decrease oligomerization  [22] . These results should be confirmed 
in larger groups of presymptomatic persons with FAD mutations as well as of those destined 
to develop late-onset AD using monoclonal conformation-dependent antibodies  [23] and 
other techniques for measuring oligomers  [8] .
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 Fig. 1. CSF A  42 levels measured by ELISA (pg/ml;  a ) and prefibrillar ( b ), fibrillar ( c ), and annular proto-
fibrillar ( d ) levels (arbitrary units) in 5 FAD mutation carriers and 2 noncarriers. Annular protofibrillar 
levels are statistically higher in FAD mutation carriers (p = 0.02). 
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